2018
Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of atherosclerotic lesions: TARGET All Comers.
Baumbach A, Lansky AJ, Onuma Y, Asano T, Johnson T, Anderson R, Kiemeneij F, Zheng M, Van Royen N, Slagboom T, Vlachojannis G, Xu B, Serruys P, Wijns W. Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of atherosclerotic lesions: TARGET All Comers. EuroIntervention 2018, 14: 1121-1128. PMID: 29901441, DOI: 10.4244/eij-d-18-00226.Peer-Reviewed Original ResearchConceptsOptical coherence tomography substudyPrimary endpointProspective multicentreStrut coveragePost-market trialDP-DESNeointimal thicknessDurable polymer drug-eluting stentsComers patient populationComplete strut coverageLate DES thrombosisSirolimus-eluting stentsStent strut coverageMean neointimal thicknessCoronary stent systemDrug-eluting stentsOCT substudyConsecutive patientsDES thrombosisPersistent inflammationPatient populationBP-DESNeointimal coverageEndothelial healingAtherosclerotic lesions
2007
Cobalt chromium stent with antiproliferative for restenosis trial in India (COSTAR I).
Kaul U, Gupta RK, Mathur A, Dani S, Sapra R, Nayak PR, Lansky A, Cristea E, Carlier S, Gambone L, Litvack F. Cobalt chromium stent with antiproliferative for restenosis trial in India (COSTAR I). Indian Heart Journal 2007, 59: 165-72. PMID: 19122251.Peer-Reviewed Original ResearchConceptsStent late lossGroup 2Group 1Late lossI trialCoronary lesionsGroup 3De novo coronary lesionsSegment late lossBinary restenosis rateNative coronary lesionsNovo coronary lesionsMulti-center registryCoronary stent systemRelease formulationExtended-release formulationSmall-caliber vesselsCobalt-chromium stentNovo lesionsPrimary endpointRestenosis TrialRestenosis rateClinical outcomesFeasibility trialClinical results